Parenteral use of medroxyprogesterone acetate as an antifertility agent in the bitch

10 kg unbred Beagle and mongrel bitches were used in each of 4 experiments (exp). 6 alpha-methyl-17 alpha-acetoxyprogesterone (MAP or medroxyprogesterone acetate) was prepared as a sterile aqueous suspension (50 mg/ml) and was used in exps 1, 2 and 3. Tritiated MAP was used in exp 4. In exp 1, 7 bitches were given 500 mg and 7 were given 50 mg subcutaneously (sc). 6 controls were used. In exp 2, 50, 100 or 250 mg were given sc, intramuscular (im) or intraperitoneal (ip) to 4 dogs at each dose level and route of administration. In exp 3, 12.5 or 25 mg was given either sc or im in 4 groups of 8 bitches each. In exp 4, a single 50 mg mixture of MAP and tritiated MAP was given to each of 3 dogs: 1 sc, 1 im, and 1 ip. Results of exp 1 showed those on 500 mg had first posttreatment estrus an average of 504 days (range of 247-730) after injection. Those on 50 mg averaged 329 days (range of 205-429). Breeding resulted in 6 live pups/litter for the controls 5.2 for those on 50 mg, and 4 for those on 500 mg. In exp 2, results showed prolonged cycling in those injected sc (295 days to estrus), while those injected im reached estrous in 225 days and those injected ip in 148 days. In exp 3, 3 on 25 mg sc had a 6 month estrous delay while 4 did when injected im. 3 of 16 given 12.5 mg sc and im had a 6 month delay in cycling. Exp 4 showed ip treated dogs had estrus 148 days after treatment, 225 days for im, and 295 days for sc. Ip treated dogs whelped 5 pups; im 7 pups; and sc, 5 pups. 7 months lapsed before nearly all of the 50 mg sc administered dose was excreted. An additional 2.5 months lapsed before estrus occurred in this dog.